Category: Funding Roundup
InspireMD looks to raise nearly $14 million in a stock-and-warrants offering to back the launch of its CGuard stent.
EndoChoice says it raised $57 million from a syndicate of prior and new backers it plans to use boost the commercial footprint of its Fuse endoscope.
EndoChoice today said it raised $57 million for its Fuse full-spectrum endoscope from a group that included prior backers and new investors.
OrthoSensor says it pulled in a $17 million funding round for its Verasense knee implant technology.
OrthoSensor said it pulled in a funding round worth nearly $17 million that it hopes will eventually add up to $19 million.
The Florida maker of knee implant placement technology disclosed the round in a recent regulatory filing.
Tandem Diabetes Care says it's planning a 5.25-million-share offering worth $60 million for its line of insulin pumps.
Tandem Diabetes Care (NSDQ:TNDM) said last week that it's planning a $60 million public offering for its line of insulin pumps.
Here's a look at some of the top legal news stories for medical device companies this week: Smith & Nephew gets in on Michelson Diagnostics Series B round; Diabetes: Valeritas registers $90m IPO; HeartFlow raises $36m for non-invasive FFR system; Bellerophon prices $60m IPO low, issues more shares; Rainbow Medical raises $25m for China ops
Israeli medical device incubator Rainbow Medical raises $25 million from Chinese investors for its new office there.
Rainbow Medical said yesterday that it pulled down $25 million from a syndicate of Chinese investors for a new operation in the People's Republic, aimed at promoting "strategic collaborations" there.
Smith & Nephew joins a $3.8 million Series B round for Michelson Diagnostics and its VivoSight OCT-based skin cancer detection device.